Evidence map›Paper›PMID 22009159›Full record

ReviewNature reviews. Endocrinology2011

Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

Marc De Hert, Johan Detraux, Ruud van Winkel, Weiping Yu, Christoph U Correll

Registry-linked trialAbstract readEvaluation StudyReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01844700 (1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain), which is not on this map. Cited by 472 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
472citing papers in PubMed, 20 pooled it
32.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01844700 phase4terminatednot on this mapstarted 2013, after this paper: background citation

1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain

TypeinterventionalSponsorNorthwell HealthRan2013 to 2014Enrolled14ConditionsHigh Risk MC4R Genotype, Low Risk MC4R Genotype, One Week or Less Antipsychotic Lifetime ExposureArmsZiprasidone, aripiprazole, quetiapine, or risperidone
3 · Its place in the literature

Who cites it

472 citing papers in PubMed, 20 syntheses or guidelines pooled it, 1,099 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Pooled it

412 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Marc De HertUniversity Psychiatric Center, Catholic University Leuven, Leuvensesteenweg 517, 3070 Kortenberg, Belgium. marc.de.hert@ uc-kortenberg.be
Johan Detraux
Ruud van Winkel
Weiping Yu
Christoph U Correll
KU Leuven · BECatholic University of America · USMaastricht University · NLZucker Hillside Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antipsychotic medications can induce cardiovascular and metabolic abnormalities (such as obesity, hyperglycemia, dyslipidemia and the metabolic syndrome) that are associated with an increased risk of type 2 diabetes mellitus and cardiovascular disease. Controversy remains about the contribution of individual antipsychotic drugs to this increased risk and whether they cause sudden cardiac death through prolongation of the corrected QT interval. Although some drug receptor-binding affinities correlate with specific cardiovascular and metabolic abnormalities, the exact pharmacological mechanisms underlying these associations remain unclear. Antipsychotic agents with prominent metabolic adverse effects might cause abnormalities in glucose and lipid metabolism via both obesity-related and obesity-unrelated molecular mechanisms. Despite existing guidelines and recommendations, many antipsychotic-drug-treated patients are not assessed for even the most easily measurable metabolic and cardiac risk factors, such as obesity and blood pressure. Subsequently, concerns have been raised over the use of these medications, especially pronounced in vulnerable pediatric patients, among whom their use has increased markedly in the past decade and seems to have especially orexigenic effects. This Review outlines the metabolic and cardiovascular risks of various antipsychotic medications in adults and children, defines the disparities in health care and finally makes recommendations for screening and monitoring of patients taking these agents.

Indexed as

AdultAntipsychotic AgentsCardiovascular DiseasesChildDeath, Sudden, CardiacDiabetes MellitusHumansMetabolic DiseasesWeight GainAntipsychotic Agents

Identifiers

PMID22009159
OpenAlexW2014026290

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.